EpiSwitch®

A New Biomarker Based Enhanced PSE Test

EpiSwitch®

Overview

EpiSwitch® PSE is an advanced blood test for prostate cancer with leading accuracy at 94%, helping you and your doctor make a fast, informed decision on appropriate care. The EpiSwitch® Prostate Screening Test has to be ordered via a clinician.

 Accuracy 94%
 NPV
 95%
 PPV 93%
 Specificity 97%
 Sensitivity 86%


The EpiSwitch® PSE

Prostate cancer is a concern for many men. Some choose to have a second or repeat PSA (Prostate Specific Antigen) test, but with 55% accuracy, this is not the answer by itself. The EpiSwitch® PSE generates results that can be trusted to accurately and quickly determine the likelihood of prostate cancer and reduce the number of men referred for unnecessary, invasive, and expensive diagnostic procedures such as a biopsy.


How the Test Works & Results

The routine PSE blood test identifies your current likelihood of prostate cancer using 3D genomic profiling, which combines 5 epigenetic biomarkers and a PSA value. These markers indicate your personal, systemic changes in your blood immune cells associated with prostate cancer.

Your doctor will receive a personalised PSE report informing you if you have a ‘low likelihood’ or ‘high likelihood’ of prostate cancer:
• A ‘low likelihood’ PSE result can offer peace of mind and reduce unnecessary biopsies and over‐treatment. This result is consistent with the absence of cancer in more than 9 out of 10 men.
• A ‘high likelihood’ PSE result can help your doctor immediately refer you to the right next step. This result is consistent with cancer being confirmed in more than 9 out of 10 men.

Benefits of Using EpiSwitch®

High Accuracy and Reliability

The EpiSwitch® PSE test has a 94% accuracy rate, significantly improving the reliability of prostate cancer screenings. This reduces the likelihood of false positives and negatives, ensuring that patients receive appropriate care swiftly and confidently.

Minimises Unnecessary Procedures

With a specificity of 97%, the EpiSwitch® PSE test effectively reduces the need for invasive procedures like biopsies by accurately identifying those at low risk, sparing patients from unnecessary stress and medical costs.

Personalised Risk Assessment

The test combines 3D genomic profiling with epigenetic biomarkers, offering a personalised evaluation of prostate cancer risk. This tailored approach enhances the precision of diagnoses, helping doctors provide targeted care based on individual risk profiles.

Who should be recommended for an EpiSwitch® test?

• Men being screened for prostate cancer;
• Men with a suspicion of prostate cancer, e.g. elevated/rising PSA or urinary symptoms;
• Men who have had an inconclusive MRI or biopsy;
• Men who have previously been treated for prostate cancer (4+ weeks after treatment).

Background

The PSE was developed by Oxford BioDynamics' (AIM:OBD) via several controlled studies and a culmination of almost a decade‐long collaboration with Imperial College NHS Trust, Imperial College London, University of East Anglia, and some of the UK’s leading prostate cancer experts as part of the PROSTAGRAM screening pilot study.

The PSE is regularly used in the USA.

How do I get tested?

Contact GFCT by email info@tgfct.org.uk. We will provide you with a Requisition Form.

1. Your clinician.

GFCT will provide an account for your clinician once they have agreed to you having a test.

2. Provide a sample.

Your clinician will collect and send a small blood sample (3ml only) using a bespoke Collection Kit.

3. Receive your results.

Within 5 days of receiving a sample, your PSE result will be securely sent to your clinician.


Download this information